Treatment of Patients with Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. The gene discussed is MAGEA3; the disease is metastatic malignant neoplasm.